Public Law 98-417

E643467

Public Law 98-417 is a landmark U.S. federal statute that created the modern generic drug approval pathway while balancing pharmaceutical innovation through patent term restoration.

Try in SPARQL Jump to: Statements Referenced by

Statements (48)

Predicate Object
instanceOf Act of Congress
United States federal statute
pharmaceutical law
abbreviation ANDA NERFINISHED
aimsTo balance pharmaceutical innovation and generic drug competition
amends Federal Food, Drug, and Cosmetic Act NERFINISHED
Title 35 of the United States Code NERFINISHED
appliesTo certain veterinary and biological products through related provisions
human prescription drugs
branchOfGovernment legislative branch of the United States
country United States of America
surface form: United States
creates mechanism for generic challenges to listed patents
modern generic drug approval pathway
paragraph I–IV certification framework for ANDAs
dateSigned 1984-09-24
effect facilitated widespread entry of lower-cost generic drugs
strengthened incentives for pharmaceutical research and development through patent term restoration
enactedBy 98th United States Congress NERFINISHED
establishes Abbreviated New Drug Application process
Orange Book patent listing framework
hasCommonName Hatch–Waxman Act NERFINISHED
hasLanguage English
hasShortTitle Drug Price Competition and Patent Term Restoration Act of 1984 NERFINISHED
jurisdiction federal law of the United States
legalCitationType Public Law NERFINISHED
namedAfter Henry Waxman NERFINISHED
Orrin Hatch NERFINISHED
policyArea health law
intellectual property law
pharmaceutical regulation
primaryPurpose to create an abbreviated approval pathway for generic drugs
to restore a portion of patent term lost during regulatory review
providesFor 180-day exclusivity for first generic applicants making certain patent challenges
market exclusivity periods for certain drug products
patent term extensions for certain drug patents
publicLawNumber P.L. 98-417 NERFINISHED
regulates approval standards for bioequivalent generic drugs
regulatoryAgencyInvolved U.S. Food and Drug Administration NERFINISHED
requires listing of relevant drug patents with the FDA
signedBy Ronald Reagan
sponsors Henry Waxman NERFINISHED
Orrin Hatch NERFINISHED
statutesAtLargeCitation 98 Stat. 1585
subjectMatter drug price competition
generic drugs
patent term restoration
pharmaceutical patents
yearEnacted 1984

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.